Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Nasal Epinephrine vs IM in Allergic Rhinitis
NCT04696822Phase 1Completed
- Sponsor
- Nasus Pharma
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epinephrine nasal spray in anaphylaxis, sponsored by Nasus Pharma. Primary endpoints: Maximum Plasma Concentration of Epinephrine at 8 hours, Time to Maximum Plasma Concentration at 8 hours and 2 more. Started Nov 2020; status: completed.
02
Drugs
epinephrine nasal spray
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT04696822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696822.